http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 11 Sep 2026 03:26:26 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/New+Coverage/JPMorgan+Starts+Dianthus+Therapeutics+%28DNTH%29+at+Overweight/27050076.html <p>JPMorgan analyst Brian Cheng initiates coverage on Dianthus Therapeutics (NASDAQ: DNTH) with a Overweight rating and a price target of $135.00.</p><p>The analyst comments: “DNTH is a clinical-stage biotech developing therapeutics for severe autoimmune diseases led by claseprubart, an active-C1s inhibitor, with an initial focus on complement-mediated neuromuscular disorders. While complement inhibition is an established tx in many neuromuscular disorders, current approved tx target the terminal pathway and are associated with infection-related safety concerns/boxed warning/REMS. DNTH is pursuing a differentiated strategy through active-C1s inhibition, which selectively blocks only the classical pathway. We believe this approach has the potential to deliver the http://www.streetinsider.com/New+Coverage/JPMorgan+Starts+Dianthus+Therapeutics+%28DNTH%29+at+Overweight/27050076.html Fri, 11 Sep 2026 03:26:26 -0400 DNTH http://www.streetinsider.com/Analyst+Comments/JPMorgan+Starts+Dianthus+Therapeutics+%28DNTH%29+at+Overweight/27050076.html <p>JPMorgan analyst Brian Cheng initiates coverage on Dianthus Therapeutics (NASDAQ: DNTH) with a Overweight rating and a price target of $135.00.</p><p>The analyst comments: “DNTH is a clinical-stage biotech developing therapeutics for severe autoimmune diseases led by claseprubart, an active-C1s inhibitor, with an initial focus on complement-mediated neuromuscular disorders. While complement inhibition is an established tx in many neuromuscular disorders, current approved tx target the terminal pathway and are associated with infection-related safety concerns/boxed warning/REMS. DNTH is pursuing a differentiated strategy through active-C1s inhibition, which selectively blocks only the classical pathway. We believe this approach has the potential to deliver the http://www.streetinsider.com/Analyst+Comments/JPMorgan+Starts+Dianthus+Therapeutics+%28DNTH%29+at+Overweight/27050076.html Fri, 11 Sep 2026 03:26:26 -0400 DNTH http://www.streetinsider.com/New+Coverage/Citi+initiates+Dianthus+Therapeutics+coverage+with+Buy+rating/27026962.html <p>Citi analyst Samantha Semenkow initiated coverage of Dianthus Therapeutics (NASDAQ: DNTH) with a Buy rating and a price target of $156.00.</p><p>Semenkow noted that the company's lead drug, claseprubart, is a complement inhibitor targeting C1s with potential applications across multiple neuromuscular indications, including generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy.</p><p>The analyst projects more than $5 billion in peak worldwide risk-adjusted revenue for claseprubart, citing proof-of-concept data that she said established a competitive efficacy profile and a dosing regimen of every two or four weeks.</p><p>Semenkow also noted two additional pipeline assets, DNTH212 and DNTH312, which the company is http://www.streetinsider.com/New+Coverage/Citi+initiates+Dianthus+Therapeutics+coverage+with+Buy+rating/27026962.html Fri, 04 Sep 2026 05:09:18 -0400 DNTH http://www.streetinsider.com/Hot+List/This+biotech+stock+still+Wolfe%27s+top+pick+as+multiple+catalysts+loomh/27001212.html <p>Wolfe Research raised its price target on a biotechnology company for the second time this year, calling it a top pick as it awaits several potential clinical catalysts over the next 12 months.</p><p>The brokerage reiterated an Outperform rating on Dianthus Therapeutics (NASDAQ: DNTH) and raised its price target to $141, up from $109, implying more than 33% upside from the last closing price. Analyst Andy Chen said he expects the stock to unlock value through its myasthenia gravis (MG) program, which he views as "a low-risk shot & potentially bigger upside on a readthrough from Biogen's litifilimab & Vor's MG http://www.streetinsider.com/Hot+List/This+biotech+stock+still+Wolfe%27s+top+pick+as+multiple+catalysts+loomh/27001212.html Mon, 31 Aug 2026 08:00:00 -0400 BIIB DNTH VOR http://www.streetinsider.com/Hot+List/This+biotech+stock+still+Wolfe%27s+top+pick+as+multiple+catalysts+loomh/27001212.html <p>Wolfe Research raised its price target on a biotechnology company for the second time this year, calling it a top pick as it awaits several potential clinical catalysts over the next 12 months.</p><p>The brokerage reiterated an Outperform rating on Dianthus Therapeutics (NASDAQ: DNTH) and raised its price target to $141, up from $109, implying more than 33% upside from the last closing price. Analyst Andy Chen said he expects the stock to unlock value through its myasthenia gravis (MG) program, which he views as "a low-risk shot & potentially bigger upside on a readthrough from Biogen's litifilimab & Vor's MG http://www.streetinsider.com/Hot+List/This+biotech+stock+still+Wolfe%27s+top+pick+as+multiple+catalysts+loomh/27001212.html Mon, 31 Aug 2026 08:00:00 -0400 BIIB DNTH VOR http://www.streetinsider.com/Hot+List/This+biotech+stock+still+Wolfe%27s+top+pick+as+multiple+catalysts+loomh/27001212.html <p>Wolfe Research raised its price target on a biotechnology company for the second time this year, calling it a top pick as it awaits several potential clinical catalysts over the next 12 months.</p><p>The brokerage reiterated an Outperform rating on Dianthus Therapeutics (NASDAQ: DNTH) and raised its price target to $141, up from $109, implying more than 33% upside from the last closing price. Analyst Andy Chen said he expects the stock to unlock value through its myasthenia gravis (MG) program, which he views as "a low-risk shot & potentially bigger upside on a readthrough from Biogen's litifilimab & Vor's MG http://www.streetinsider.com/Hot+List/This+biotech+stock+still+Wolfe%27s+top+pick+as+multiple+catalysts+loomh/27001212.html Mon, 31 Aug 2026 08:00:00 -0400 BIIB DNTH VOR http://www.streetinsider.com/Hot+List+Pro/This+biotech+stock+still+Wolfe%27s+top+pick+as+multiple+catalysts+loomh/27001212.html <p>Wolfe Research raised its price target on a biotechnology company for the second time this year, calling it a top pick as it awaits several potential clinical catalysts over the next 12 months.</p><p>The brokerage reiterated an Outperform rating on Dianthus Therapeutics (NASDAQ: DNTH) and raised its price target to $141, up from $109, implying more than 33% upside from the last closing price. Analyst Andy Chen said he expects the stock to unlock value through its myasthenia gravis (MG) program, which he views as "a low-risk shot & potentially bigger upside on a readthrough from Biogen's litifilimab & Vor's MG http://www.streetinsider.com/Hot+List+Pro/This+biotech+stock+still+Wolfe%27s+top+pick+as+multiple+catalysts+loomh/27001212.html Mon, 31 Aug 2026 08:00:00 -0400 BIIB DNTH VOR http://www.streetinsider.com/Hot+List+Pro/This+biotech+stock+still+Wolfe%27s+top+pick+as+multiple+catalysts+loomh/27001212.html <p>Wolfe Research raised its price target on a biotechnology company for the second time this year, calling it a top pick as it awaits several potential clinical catalysts over the next 12 months.</p><p>The brokerage reiterated an Outperform rating on Dianthus Therapeutics (NASDAQ: DNTH) and raised its price target to $141, up from $109, implying more than 33% upside from the last closing price. Analyst Andy Chen said he expects the stock to unlock value through its myasthenia gravis (MG) program, which he views as "a low-risk shot & potentially bigger upside on a readthrough from Biogen's litifilimab & Vor's MG http://www.streetinsider.com/Hot+List+Pro/This+biotech+stock+still+Wolfe%27s+top+pick+as+multiple+catalysts+loomh/27001212.html Mon, 31 Aug 2026 08:00:00 -0400 BIIB DNTH VOR http://www.streetinsider.com/Hot+List+Pro/This+biotech+stock+still+Wolfe%27s+top+pick+as+multiple+catalysts+loomh/27001212.html <p>Wolfe Research raised its price target on a biotechnology company for the second time this year, calling it a top pick as it awaits several potential clinical catalysts over the next 12 months.</p><p>The brokerage reiterated an Outperform rating on Dianthus Therapeutics (NASDAQ: DNTH) and raised its price target to $141, up from $109, implying more than 33% upside from the last closing price. Analyst Andy Chen said he expects the stock to unlock value through its myasthenia gravis (MG) program, which he views as "a low-risk shot & potentially bigger upside on a readthrough from Biogen's litifilimab & Vor's MG http://www.streetinsider.com/Hot+List+Pro/This+biotech+stock+still+Wolfe%27s+top+pick+as+multiple+catalysts+loomh/27001212.html Mon, 31 Aug 2026 08:00:00 -0400 BIIB DNTH VOR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dianthus+Therapeutics%2C++++For%3A+Aug+19++Filed+by%3A+Read+Simon/26951360.html si-local-file:///var/storage/secattach/20260819/26951360.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dianthus+Therapeutics%2C++++For%3A+Aug+19++Filed+by%3A+Read+Simon/26951360.html Wed, 19 Aug 2026 18:03:00 -0400 DNTH O.38286623 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dianthus+Therapeutics%2C++++For%3A+Aug+19++Filed+by%3A+Read+Simon/26951360.html si-local-file:///var/storage/secattach/20260819/26951360.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dianthus+Therapeutics%2C++++For%3A+Aug+19++Filed+by%3A+Read+Simon/26951360.html Wed, 19 Aug 2026 18:03:00 -0400 DNTH O.38286623 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dianthus+Therapeutics%2C++++For%3A+Aug+13++Filed+by%3A+Veness+Adam+M/26931491.html si-local-file:///var/storage/secattach/20260814/26931491.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dianthus+Therapeutics%2C++++For%3A+Aug+13++Filed+by%3A+Veness+Adam+M/26931491.html Fri, 14 Aug 2026 16:33:00 -0400 DNTH O.38286623 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dianthus+Therapeutics%2C++++For%3A+Aug+13++Filed+by%3A+Veness+Adam+M/26931491.html si-local-file:///var/storage/secattach/20260814/26931491.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dianthus+Therapeutics%2C++++For%3A+Aug+13++Filed+by%3A+Veness+Adam+M/26931491.html Fri, 14 Aug 2026 16:33:00 -0400 DNTH O.38286623 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Dianthus+Therapeutics%2C+++++++++++++++++Filed+by%3A+Sirenia+Capital+Management+LP/26925195.html si-local-file:///var/storage/secattach/20260814/26925195.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Dianthus+Therapeutics%2C+++++++++++++++++Filed+by%3A+Sirenia+Capital+Management+LP/26925195.html Fri, 14 Aug 2026 08:33:00 -0400 DNTH O.38286623 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Dianthus+Therapeutics%2C+++++++++++++++++Filed+by%3A+Sirenia+Capital+Management+LP/26925195.html si-local-file:///var/storage/secattach/20260814/26925195.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Dianthus+Therapeutics%2C+++++++++++++++++Filed+by%3A+Sirenia+Capital+Management+LP/26925195.html Fri, 14 Aug 2026 08:33:00 -0400 DNTH O.38286623 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Dianthus+Therapeutics%2C+++++++++++++++++Filed+by%3A+WELLINGTON+MANAGEMENT+GROUP+LLP/26920791.html si-local-file:///var/storage/secattach/20260813/26920791.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Dianthus+Therapeutics%2C+++++++++++++++++Filed+by%3A+WELLINGTON+MANAGEMENT+GROUP+LLP/26920791.html Thu, 13 Aug 2026 16:06:00 -0400 DNTH O.38286623 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Dianthus+Therapeutics%2C+++++++++++++++++Filed+by%3A+WELLINGTON+MANAGEMENT+GROUP+LLP/26920791.html si-local-file:///var/storage/secattach/20260813/26920791.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Dianthus+Therapeutics%2C+++++++++++++++++Filed+by%3A+WELLINGTON+MANAGEMENT+GROUP+LLP/26920791.html Thu, 13 Aug 2026 16:06:00 -0400 DNTH O.38286623 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dianthus+Therapeutics%2C++++For%3A+Aug+10++Filed+by%3A+McGeorge+Anne/26907046.html si-local-file:///var/storage/secattach/20260811/26907046.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dianthus+Therapeutics%2C++++For%3A+Aug+10++Filed+by%3A+McGeorge+Anne/26907046.html Tue, 11 Aug 2026 17:15:00 -0400 DNTH O.38286623 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dianthus+Therapeutics%2C++++For%3A+Aug+10++Filed+by%3A+McGeorge+Anne/26907046.html si-local-file:///var/storage/secattach/20260811/26907046.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dianthus+Therapeutics%2C++++For%3A+Aug+10++Filed+by%3A+McGeorge+Anne/26907046.html Tue, 11 Aug 2026 17:15:00 -0400 DNTH O.38286623 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dianthus+Therapeutics%2C++++For%3A+Aug+10++Filed+by%3A+Read+Simon/26906983.html si-local-file:///var/storage/secattach/20260811/26906983.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dianthus+Therapeutics%2C++++For%3A+Aug+10++Filed+by%3A+Read+Simon/26906983.html Tue, 11 Aug 2026 17:10:00 -0400 DNTH O.38286623 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dianthus+Therapeutics%2C++++For%3A+Aug+10++Filed+by%3A+Read+Simon/26906983.html si-local-file:///var/storage/secattach/20260811/26906983.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dianthus+Therapeutics%2C++++For%3A+Aug+10++Filed+by%3A+Read+Simon/26906983.html Tue, 11 Aug 2026 17:10:00 -0400 DNTH O.38286623 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dianthus+Therapeutics%2C++++For%3A+Aug+07++Filed+by%3A+Veness+Adam+M/26906962.html si-local-file:///var/storage/secattach/20260811/26906962.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dianthus+Therapeutics%2C++++For%3A+Aug+07++Filed+by%3A+Veness+Adam+M/26906962.html Tue, 11 Aug 2026 17:09:00 -0400 DNTH O.38286623 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dianthus+Therapeutics%2C++++For%3A+Aug+07++Filed+by%3A+Veness+Adam+M/26906962.html si-local-file:///var/storage/secattach/20260811/26906962.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dianthus+Therapeutics%2C++++For%3A+Aug+07++Filed+by%3A+Veness+Adam+M/26906962.html Tue, 11 Aug 2026 17:09:00 -0400 DNTH O.38286623 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Dianthus+Therapeutics%2C+++++++++++++++++Filed+by%3A+Veness+Adam+M/26898852.html si-local-file:///var/storage/secattach/20260810/26898852.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Dianthus+Therapeutics%2C+++++++++++++++++Filed+by%3A+Veness+Adam+M/26898852.html Mon, 10 Aug 2026 16:51:00 -0400 DNTH O.38286623 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Dianthus+Therapeutics%2C+++++++++++++++++Filed+by%3A+Veness+Adam+M/26898852.html si-local-file:///var/storage/secattach/20260810/26898852.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Dianthus+Therapeutics%2C+++++++++++++++++Filed+by%3A+Veness+Adam+M/26898852.html Mon, 10 Aug 2026 16:51:00 -0400 DNTH O.38286623